GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » Research & Development

Sinopharm Tech Holdings (HKSE:08156) Research & Development : HK$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sinopharm Tech Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sinopharm Tech Holdings's Research & Development for the three months ended in Dec. 2024 was HK$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil.

Sinopharm Tech Holdings Research & Development Historical Data

The historical data trend for Sinopharm Tech Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Tech Holdings Research & Development Chart

Sinopharm Tech Holdings Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinopharm Tech Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sinopharm Tech Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Tech Holdings  (HKSE:08156) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sinopharm Tech Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Sinopharm Tech Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Tech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » Research & Development
Comparable Companies
HKSE:08100 HKSE:08131 HKSE:08290 HKSE:08036 HKSE:08048 HKSE:08060 HKSE:08018 HKSE:08205 HKSE:08071 HKSE:02246 XTER:SAP CRM NOW INTU UBER ADBE TSX:SHOP ADP MSTR APP
Traded in Other Exchanges
N/A
Address
Ruttonjee Centre, 11 Duddell Street, Unit 1802, 18th Floor, Ruttonjee House, Hong Kong Central, Hong Kong, HKG
Website
https://www.sinopharmtech.com.hk
Sinopharm Tech Holdings Ltd is an investment holding company. The company's operating segment includes Internet Plus services; Supply chain services; and Manufacturing and distribution of personal protective equipment. It generates maximum revenue from Supply chain services segment, which includes provision of supply chain management, data analysis and related services and trading of related goods, and trading of medial and related products. Geographically, it derives a majority of revenue from Hong Kong.
Executives
Chiu Sin Nang Kenny 2201 Interest of corporation controlled by you
Creative Big Limited 2101 Beneficial owner
Integrated Asset Management (asia) Limited 2101 Beneficial owner
Yam Tak Cheung 2201 Interest of corporation controlled by you
Quantum Worldwide Investment Limited 2101 Beneficial owner
Best Frontier Investments Limited
Chan Kin Ho Philip 2201 Interest of corporation controlled by you
Lam Yui Keung 2201 Interest of corporation controlled by you
Sinopharm Traditional Chinese Medicine Overseas Holdings Limited 2101 Beneficial owner
Main Key Investments Limited 2201 Interest of corporation controlled by you
Guo Lei 2201 Interest of corporation controlled by you
Chan Tung Mei 2202 Interest of your spouse
Cheung Kwai Lan 2201 Interest of corporation controlled by you
Tse Siu Hoi 2101 Beneficial owner
Gam Star China Equity (a Sub-fund Of Gam Star Fund P.l.c.) 2102 Investment manager

Sinopharm Tech Holdings Headlines

No Headlines